3,221
Participants
Start Date
June 30, 2007
Primary Completion Date
January 31, 2009
Study Completion Date
January 31, 2009
Enoxaparin
40 mg, administered once daily by subcutaneous injection, for 12 days
Apixaban
2.5 mg, administered twice daily as tablets, for 12 days
Enoxaparin-matching placebo
Administered once daily by subcutaneous injection
Apixaban-matching placebo
Oral tablet administered twice daily
Local Institution, Manila
Local Institution, Vienna
Local Institution, Quezon City
Local Institution, Quezon City
Local Institution, Vienna
Local Institution, Gjettum
Local Institution, Antwerp
Local Institution, Johannesburg
Local Institution, Johannesburg
Local Institution, Randburg
Local Institution, Kongsvinger
Local Institution, Hvidovre
Local Institution, Wiener Neustadt
Local Institution, Hellerup
Local Institution, Hasselt
Local Institution, Linz
Local Institution, Wels
Local Institution, Kolding
Local Institution, Innsbruck
Local Institution, Ålesund
Local Institution, Szeged
Local Institution, Worcester
Local Institution, Szekszárd
Local Institution, Somerset West
Local Institution, Tygerberg
Local Institution, Graz
Local Institution, Viborg
Local Institution, Safed
Local Institution, Brandenburg
Local Institution, Santiago de Compostela
Local Institution, Kremmen Ot Sommerfeld
Local Institution, Cherkassy
Local Institution, Aguascalientes
Local Institution, San Donato Milanese (Mi)
Local Institution, Madrid
Local Institution, Belo Horizonte - Mg
Local Institution, Pordenone
Local Institution, Abano Terme (Pd)
Local Institution, Bologna
Local Institution, Bochum
Local Institution, Zapopan
Local Institution, Valencia
Local Institution, Dnipropetrovsk
Local Institution, Petah Tikva
Local Institution, Kuala Lumpur
Local Institution, Tel Litwinsky
Local Institution, Kuala Lumpur
Local Institution, Chernivtsy
Local Institution, Witten
Local Institution, Saint-Saulve
Local Institution, Frankfurt am Main
Local Institution, Tel Aviv
Local Institution, Frankfurt
Local Institution, Paris
Local Institution, Paris
Local Institution, Paris
Local Institution, Ivano-Frankivsk
Local Institution, San Luis Potosí City
Local Institution, Rheinfelden
Local Institution, Hermosillo
Local Institution, Jeruselem
Local Institution, Veracruz
Local Institution, Bad Mergentheim
Local Institution, Monaco
Local Institution, Sevastopol
Local Institution, Beijing
Local Institution, Beijing
Local Institution, Moscow
Local Institution, Ludhiana
Local Institution, Singapore
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Shanghai
Local Institution, Shanghai
Local Institution, Shanghai
Local Institution, Qingdao
Local Institution, Rostov-on-Don
Local Institution, Ahmedabad
Local Institution, Baroda
Local Institution, Lipetsk
Local Institution, Kazan'
Local Institution, Samara
Local Institution, Chelyabinsk
Local Institution, Singapore
Local Institution, Bangalore
Local Institution, Mangalore
Local Institution, Santiago
Local Institution, Santiago
Local Institution, São Paulo
Local Institution, Bogotá
Local Institution, Bogotá
Local Institution, Medellín
Local Institution, Santiago de Cali
Local Institution, Brno
Local Institution, Chomutov
Local Institution, Pardubice
Local Institution, Prague
Local Institution, Uherské Hradiště
Local Institution, Nice
Local Institution, Dresden
Local Institution, Halle/S
Local Institution, Roma
Local Institution, Bytom
Local Institution, Gdansk
Local Institution, Warsaw
Local Institution, Wroclaw
Local Institution, Pretoria
Local Institution, Jeonnam
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Badalona-Barcelona
Local Institution, Barcelona
Local Institution, Barcelona
Local Institution, Barcelona
Local Institution, Borås
Local Institution, Kyiv
Local Institution, Kyiv
Local Institution, London
Local Institution, Epsom
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY